NeuroVive Pharmaceutical AB IPO-Jahr
Was ist das IPO-Jahr von NeuroVive Pharmaceutical AB?
IPO-Jahr von NeuroVive Pharmaceutical AB ist 2020
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Miscellaneous Sektor auf LSE im Vergleich zu NeuroVive Pharmaceutical AB
Was macht NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Unternehmen mit ipo-jahr ähnlich NeuroVive Pharmaceutical AB
- Acusensus Ltd hat IPO-Jahr von 2019
- Grayscale Ethereum Trust (ETH) hat IPO-Jahr von 2019
- Powerwrap Ltd hat IPO-Jahr von 2019
- Powerwrap hat IPO-Jahr von 2019
- National Rural Utilities Cooper hat IPO-Jahr von 2019
- Listed Funds Trust hat IPO-Jahr von 2019
- NeuroVive Pharmaceutical AB hat IPO-Jahr von 2020
- Globally Local Technologies hat IPO-Jahr von 2021
- uniQure N.V hat IPO-Jahr von 2021
- Trustpilot plc hat IPO-Jahr von 2021
- IQVIA hat IPO-Jahr von 2021
- ACTIA S.A hat IPO-Jahr von 2021
- Remark hat IPO-Jahr von 2021